Pure Global

A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients - Trial NCT06315257

Access comprehensive clinical trial information for NCT06315257 through Pure Global AI's free database. This Phase 1 trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and is currently Not yet recruiting. The study focuses on Cervical Cancer. Target enrollment is 32 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06315257
Phase 1
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06315257
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients
A Randomized, Open-label Clinical Trial to Assess the Safety, Feasibility and Immunogenicity of Adjuvant PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients

Study Focus

Cervical Cancer

PVX7

Interventional

drug

Sponsor & Location

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Timeline & Enrollment

Phase 1

Aug 01, 2024

Mar 01, 2027

32 participants

Primary Outcome

Safety of PVX7 as assessed by adverse events,Feasibility of PVX7

Summary

A Feasibility Trial of PVX7 vaccine in advanced cervical cancer patients who have completed
 primary definitive therapy.

ICD-10 Classifications

Severe cervical dysplasia, not elsewhere classified
Mild cervical dysplasia
Moderate cervical dysplasia
Carcinoma in situ: Cervix, unspecified
Cervical root disorders, not elsewhere classified

Data Source

ClinicalTrials.gov

NCT06315257

Non-Device Trial